loading
前日終値:
$11.38
開ける:
$11.58
24時間の取引高:
4.36M
Relative Volume:
0.71
時価総額:
$7.85B
収益:
$125.68M
当期純損益:
$4.81B
株価収益率:
2.0442
EPS:
5.65
ネットキャッシュフロー:
$-781.21M
1週間 パフォーマンス:
+0.96%
1か月 パフォーマンス:
+1.32%
6か月 パフォーマンス:
+3.40%
1年 パフォーマンス:
+7.54%
1日の値動き範囲:
Value
$11.35
$11.64
1週間の範囲:
Value
$11.31
$11.64
52週間の値動き範囲:
Value
$8.73
$13.05

Roivant Sciences Ltd Stock (ROIV) Company Profile

Name
名前
Roivant Sciences Ltd
Name
セクター
Healthcare (1164)
Name
電話
441-295-5950
Name
住所
7TH FLOOR, 50 BROADWAY, LONDON
Name
職員
750
Name
Twitter
Name
次回の収益日
2025-02-10
Name
最新のSEC提出書
Name
ROIV's Discussions on Twitter

ROIV を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
ROIV
Roivant Sciences Ltd
11.55 7.74B 125.68M 4.81B -781.21M 5.65
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 121.28B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 32.08B 3.81B -644.79M -669.77M -6.24

Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-07-10 再開されました Goldman Buy
2024-02-15 開始されました Wolfe Research Outperform
2024-01-05 開始されました Piper Sandler Overweight
2023-12-12 開始されました Deutsche Bank Buy
2023-10-17 開始されました Guggenheim Buy
2023-06-08 開始されました BofA Securities Neutral
2022-10-27 開始されました JP Morgan Overweight
2022-05-23 開始されました SVB Leerink Outperform
2022-04-29 開始されました Cantor Fitzgerald Overweight
2021-12-15 開始されました Goldman Buy
2021-11-08 開始されました H.C. Wainwright Buy
2021-10-28 開始されました Citigroup Buy
2021-10-26 開始されました Cowen Outperform
2021-10-26 開始されました Jefferies Buy
2021-10-26 開始されました Truist Buy
すべてを表示

Roivant Sciences Ltd (ROIV) 最新ニュース

pulisher
Jul 25, 2025

Is Roivant Sciences Ltd. a good long term investmentUnbelievable profit margins - Autocar Professional

Jul 25, 2025
pulisher
Jul 25, 2025

Roivant Sciences (ROIV) Anticipated to Benefit from Brepocitinib Developments | ROIV Stock News - GuruFocus

Jul 25, 2025
pulisher
Jul 25, 2025

Goldman Sachs Resumes Roivant Sciences (ROIV) Coverage with ‘Buy’ Rating - MSN

Jul 25, 2025
pulisher
Jul 25, 2025

Vivek Ramaswamy to welcome third child soon: Meet his wife and his two elder sons - Times of India

Jul 25, 2025
pulisher
Jul 24, 2025

Roivant Sciences Ltd. Stock Analysis and ForecastFree Stock Market Beginners Guide - Autocar Professional

Jul 24, 2025
pulisher
Jul 23, 2025

Roivant Sciences’ president Venker sells $1.15 million in shares By Investing.com - Investing.com South Africa

Jul 23, 2025
pulisher
Jul 23, 2025

Roivant Sciences’ president Venker sells $1.15 million in shares - Investing.com Australia

Jul 23, 2025
pulisher
Jul 23, 2025

Roivant Sciences President Eric Venker Sells 100k Shares at $11.52, Buys 100k at $3.85. - AInvest

Jul 23, 2025
pulisher
Jul 23, 2025

10 Best Biotech Stocks to Buy According to Billionaire Steve Cohen - Insider Monkey

Jul 23, 2025
pulisher
Jul 23, 2025

What drives Roivant Sciences Ltd. stock priceExceptional risk-adjusted gains - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 23, 2025

What analysts say about Roivant Sciences Ltd. stockTriple-digit profit margins - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 18, 2025

(ROIV) Investment Analysis and Advice - news.stocktradersdaily.com

Jul 18, 2025
pulisher
Jul 10, 2025

Goldman Sachs resumes Roivant Sciences stock coverage with Buy rating By Investing.com - Investing.com South Africa

Jul 10, 2025
pulisher
Jul 10, 2025

Goldman Sachs resumes Roivant Sciences stock coverage with Buy rating - Investing.com India

Jul 10, 2025
pulisher
Jul 07, 2025

How to Take Advantage of moves in (ROIV) - news.stocktradersdaily.com

Jul 07, 2025
pulisher
Jul 05, 2025

Roivant Sciences: Booming Pipeline Without Product Revenues Creates Valuation Riddle - Seeking Alpha

Jul 05, 2025
pulisher
Jun 26, 2025

'Just the beginning': Vivek Ramaswamy breaks record in raising fund for Guv election campaign, $8.5 milli - Times of India

Jun 26, 2025
pulisher
Jun 25, 2025

Hedge Fund and Insider Trading News: Ken Griffin, Warren Buffett, Michael Burry, AQR Capital Management, Tiger Global Management, Amplify Energy Corp (AMPY), Roivant Sciences ltd (ROIV), and More - Insider Monkey

Jun 25, 2025
pulisher
Jun 24, 2025

Roivant Sciences Subsidiary Pulmovant Publishes Positive Phase 1 Data for Inhaled PH Treatment Mosliciguat - Yahoo Finance

Jun 24, 2025
pulisher
Jun 23, 2025

Roivant Sciences (ROIV): Ramaswamy sells $13 million in shares - Investing.com

Jun 23, 2025
pulisher
Jun 18, 2025

HC Wainwright & Co. Reiterates Buy Rating for Roivant Sciences (ROIV) | ROIV Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Cantor Fitzgerald reiterates overweight rating on Roivant Sciences stock By Investing.com - Investing.com India

Jun 18, 2025
pulisher
Jun 18, 2025

H.C. Wainwright reiterates buy rating on Roivant Sciences stock By Investing.com - Investing.com India

Jun 18, 2025
pulisher
Jun 18, 2025

Guggenheim maintains buy rating on Roivant Sciences stock amid DM study - Investing.com India

Jun 18, 2025
pulisher
Jun 18, 2025

JPMorgan Maintains Positive Outlook on Roivant Sciences (ROIV) | ROIV Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 17, 2025

Roivant (ROIV) Hosts Investor Webinar on Brepocitinib's Role in Dermatomyositis | ROIV Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 16, 2025

Long Term Trading Analysis for (ROIV) - news.stocktradersdaily.com

Jun 16, 2025
pulisher
Jun 16, 2025

Roivant (ROIV) Publishes Promising Phase 1 Results for Inhaled M - GuruFocus

Jun 16, 2025
pulisher
Jun 10, 2025

Roivant Sciences at Goldman Sachs Conference: Strategic Execution Focus By Investing.com - Investing.com South Africa

Jun 10, 2025
pulisher
Jun 10, 2025

Roivant Sciences at Goldman Sachs Conference: Strategic Execution Focus - Investing.com Australia

Jun 10, 2025
pulisher
Jun 09, 2025

Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis - Yahoo Finance

Jun 09, 2025
pulisher
Jun 09, 2025

Rare Disease Breakthrough: Roivant Reveals Brepocitinib Data for Dermatomyositis Treatment - Stock Titan

Jun 09, 2025
pulisher
Jun 07, 2025

Major Shareholder Cashes Out Millions in Roivant Sciences Stock - TipRanks

Jun 07, 2025
pulisher
Jun 04, 2025

(ROIV) Trading Advice - news.stocktradersdaily.com

Jun 04, 2025
pulisher
May 31, 2025

Vivek Ramaswamy’s firm wants to buy biotech companies to bet on bitcoin - MSN

May 31, 2025
pulisher
May 31, 2025

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $324,000 Stock Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV) - Defense World

May 31, 2025
pulisher
May 31, 2025

Roivant Sciences Earnings Call: Balancing Growth and Challenges - MSN

May 31, 2025
pulisher
May 30, 2025

Roivant outlines packed 36-month launch and data cycle with under $5B cash reserve and multi-blockbuster pipeline - MSN

May 30, 2025
pulisher
May 30, 2025

Decoding Roivant Sciences Ltd (ROIV): A Strategic SWOT Insight - GuruFocus

May 30, 2025
pulisher
May 30, 2025

Roivant Sciences Ltd. (NASDAQ:ROIV) Q4 2024 Earnings Call Transcript - Insider Monkey

May 30, 2025
pulisher
May 30, 2025

Roivant Sciences Full Year 2025 Earnings: EPS Beats Expectations, Revenues Lag - simplywall.st

May 30, 2025
pulisher
May 30, 2025

While Wall Street Naps, These 10 Stocks Run Wild - Insider Monkey

May 30, 2025
pulisher
May 30, 2025

Why Roivant Sciences Ltd. (ROIV) Surged On Thursday - Insider Monkey

May 30, 2025

Roivant Sciences Ltd (ROIV) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Roivant Sciences Ltd (ROIV) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Venker Eric
President & Immunovant CEO
Jul 21 '25
Sale
11.52
100,000
1,152,000
1,462,223
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
大文字化:     |  ボリューム (24 時間):